论文部分内容阅读
人类B细胞非霍奇金淋巴瘤(NHL)细胞表面Ig的克隆性表达为单克隆抗体(单抗)治疗提供了目标。限制该治疗方法的重要问题是多数患者的少数肿瘤细胞的表面Ig发生突变,从而逃脱单抗的作用。作者试图通过联用短疗程化疗和单抗治疗减少独特型阴性的变异细胞的出现。病例选择:(1)NHL复发患者;(2)外周淋巴结直径>2cm;(3)生存期超过1年;(4)不合并其他恶性肿瘤或无其他重要临床问题;(5)活检组织的免疫表型分析证明克隆性表面Ig的存在;(6)抗独特型抗体能与90%以上的肿瘤细胞反应。共有13例患者符合上述条件,进入研究。每个患者用单克隆抗独特型抗体治疗2个疗程,2个疗程之间间隔4周,每疗程用抗体的一半。在第二
The clonal expression of Ig on the surface of human B-cell non-Hodgkin’s lymphoma (NHL) cells provides a target for monoclonal antibody (monoclonal antibody) therapy. An important problem that limits this treatment is that most patients have a mutation in the surface Ig of a few tumor cells, thereby escaping the effect of monoclonal antibodies. The authors attempted to reduce the appearance of idiotype-negative variant cells by using a combination of short-course chemotherapy and monoclonal antibody therapy. Case selection: (1) Relapsed NHL patients; (2) Peripheral lymph node diameter> 2 cm; (3) Longer survival than 1 year; (4) No other malignant tumors or other important clinical problems; (5) Immunization of biopsy tissue Phenotypic analysis demonstrated the presence of clonal surface Ig; (6) Anti-idiotypic antibodies reacted with more than 90% of tumor cells. A total of 13 patients met the above conditions and entered the study. Each patient was treated with a monoclonal anti-idiotypic antibody for two courses, two courses of time between the four weeks, each treatment with half of the antibody. In the second